#USA #New York #Actimab-A #Actinium Pharmaceuticals #Iomab-ACT

Actinium Pharmaceuticals Secures Important Patent Allowances

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), a trailblazer in targeted radiotherapies, has recently made headlines by receiving Notices of Allowance from the Canadian Intellectual Property Office (CIPO) regarding two crucial patent applications related to their innovative therapies: Actimab-A and Iomab-ACT. This step marks a significant advancement in the company’s intellectual property portfolio, particularly as it pertains to the treatment of hematologic malignancies and gene-edited cell-based therapies.

Strengthening Global Patent Strategy

The approvals represent a robust expansion of Actinium’s intellectual property landscape, which now boasts around 250 patents and pending applications submitted worldwide. The strategic nature of these patents is mapped directly to Actinium’s priorities in hematological cancers, thereby fortifying its emerging global market presence. Following the examination by CIPO, the patents are anticipated to be issued in due course, contributing further to the company’s extensive protective measures around its innovations.

Adeela Kamal, Ph.D., the Executive Vice President of Research and Development at Actinium, commented on the significance of these allowances: “These two allowances reflect the breadth and depth of the innovation across our radiotherapy platform and our commitment to protecting it in every key market.” This statement underlines the confidence the company exhibits in its proprietary technologies and enhances the overall market credibility of its pioneering therapies.

Actimab-A and the Fight Against AML

The approved patent concerning Actimab-A integrates its use with the chemotherapy regimen known as CLAG-M for treating acute myeloid leukemia (AML). This combination is particularly noteworthy as Actimab-A is currently one of Actinium's most promising clinical-stage candidates, presenting as a potential cornerstone in the therapy for myeloid malignancies. This Canadian allowance builds upon an already granted counterpart patent in Japan, and applications are currently pending in the United States and Europe. The patent, which originates from Application No. 3,087,346, titled "Combination Immunotherapy and Chemotherapy for the Treatment of a Hematological Malignancy,” will extend its patent term into January 2039, thereby ensuring comprehensive protection for the duration of its expected market life.

Iomab-ACT as a Conditioning Approach

The second patent allowance pertains to Iomab-ACT, a targeted conditioning agent aimed at preparing patients for gene-edited cell-based therapies. This innovative approach is crucial for enhancing the efficacy of adoptive cell therapies, which are increasingly becoming a focal point in cancer treatment. The Canadian approval furthers the existing U.S. patent and expands the application spectrum for Iomab-ACT across multiple key international markets, with additional applications currently pending. This strategic patent, filing from Application No. 3,078,963 titled "Anti-CD45-Based Conditioning Methods and Uses Thereof in Conjunction with Gene-Edited Cell-Based Therapies,” will remain effective until October 2038, granting Actinium essential coverage as it advances these therapies into clinical use.

Actinium's Vision for Cancer Treatment

Founded on a mission to transform cancer treatment, Actinium Pharmaceuticals aims to improve patient outcomes through innovative radioconjugates that leverage advanced tumor biology and radiochemistry. The company develops cutting-edge radiopharmaceuticals targeting solid tumors and hematological malignancies. Its pipeline reflects its commitment to impactful research, focusing on three primary areas: solid tumor therapeutics such as ATNM-400 and Actimab-A, Actimab-A for AML and myelodysplastic syndrome (MDS) in partnership with the National Cancer Institute (NCI), and Iomab-based conditioning agents.

According to recent reports, Actinium’s preclinical solid tumor programs are also under development, alongside its strategic initiatives to expand its patent portfolio further, which currently includes about 250 patents and patent applications, such as those related to the cyclotron-based production of Ac-225. The company continues to pursue innovative pathways to ensure that patients have access to the latest advances in cancer therapies as it forges ahead on its mission to enhance treatment landscapes. For more detailed insights into Actinium's innovative approaches and ongoing projects, partners and investors are encouraged to explore www.actiniumpharma.com.

In summary, these patent allowances are a testament to Actinium Pharmaceuticals’ commitment to expand and defend its intellectual property globally as it pushes forward with initiatives that have the potential to make a significant impact in the realm of cancer treatment.